BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Woodford investment, $M Immunocore Ltd. $320.0 Kymab Group Ltd. $190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Woodford investment, $M Immunocore Ltd. $320.0 Kymab Group Ltd. $190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd....
BioCentury | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

...year. Century's CSO will be Luis Borges, the former CSO of NK cell therapy company Cell Medica Ltd....
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Therapeutics plc (NASDAQ:ORTX) (C) $180.7 8/13/18 Autologous ex vivo gene therapy Endocrine/ metabolic, hematology, neurology Cell Medica Ltd....
BioCentury | Apr 30, 2019
Clinical News

April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

...Gene Therapy Data" ). Cell Medica reports first clinical data for CAR NK T cell therapy Cell Medica Ltd....
...CD123 - IL-3 receptor α; GD2 - Ganglioside GD2 Brian Moy, Assistant Editor AXO-Lenti-PD, OXB-102 XmAb14045, CD3 x CD123 Cell Medica Ltd. Xencor...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

...models. Dotti is a professor of microbiology and immunology. He is also an advisor to Cell Medica Ltd....
...and Institutions Mentioned American Society of Hematology, Washington, D.C. bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Cell Medica Ltd....
BioCentury | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

...chief development officer positions at Delenex Therapeutics AG and Auris Medical Holding AG (NASDAQ:EARS), respectively. Cell Medica Ltd....
BioCentury | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

...primary ways: manufacturing speed, cost, cell quality and solid tumor penetration. Chris Nowers, CEO of Cell Medica Ltd....
...in a CAR, the cells can be directed against other cancer types. C. NKT cells. Cell Medica Ltd....
...from donor-derived T cells to spare them from antibody-mediated killing. (2) Adaptimmune Therapeutics plc (NASDQ:ADAP), Cell Medica...
BioCentury | Sep 28, 2018
Clinical News

Cell Medica doses first neuroblastoma patient with NK cell therapy

...maximum tolerated dose (MTD) as its primary endpoint and antitumor response as its secondary endpoint. Cell Medica Ltd....
...neuroblastoma Endpoint: Maximum tolerated dose (MTD); antitumor response Status: Phase I started Milestone: NA Jaime De Leon CMD-501 Cell Medica Ltd. Ganglioside...
BioCentury | Aug 1, 2018
Company News

Management tracks: Hologic, Tricidia

...CMO. He was chief clinical development officer at Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Cancer immunotherapy company Cell Medica Ltd....
Items per page:
1 - 10 of 45
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Woodford investment, $M Immunocore Ltd. $320.0 Kymab Group Ltd. $190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Woodford investment, $M Immunocore Ltd. $320.0 Kymab Group Ltd. $190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd....
BioCentury | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

...year. Century's CSO will be Luis Borges, the former CSO of NK cell therapy company Cell Medica Ltd....
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Therapeutics plc (NASDAQ:ORTX) (C) $180.7 8/13/18 Autologous ex vivo gene therapy Endocrine/ metabolic, hematology, neurology Cell Medica Ltd....
BioCentury | Apr 30, 2019
Clinical News

April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

...Gene Therapy Data" ). Cell Medica reports first clinical data for CAR NK T cell therapy Cell Medica Ltd....
...CD123 - IL-3 receptor α; GD2 - Ganglioside GD2 Brian Moy, Assistant Editor AXO-Lenti-PD, OXB-102 XmAb14045, CD3 x CD123 Cell Medica Ltd. Xencor...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

...models. Dotti is a professor of microbiology and immunology. He is also an advisor to Cell Medica Ltd....
...and Institutions Mentioned American Society of Hematology, Washington, D.C. bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Cell Medica Ltd....
BioCentury | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

...chief development officer positions at Delenex Therapeutics AG and Auris Medical Holding AG (NASDAQ:EARS), respectively. Cell Medica Ltd....
BioCentury | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

...primary ways: manufacturing speed, cost, cell quality and solid tumor penetration. Chris Nowers, CEO of Cell Medica Ltd....
...in a CAR, the cells can be directed against other cancer types. C. NKT cells. Cell Medica Ltd....
...from donor-derived T cells to spare them from antibody-mediated killing. (2) Adaptimmune Therapeutics plc (NASDQ:ADAP), Cell Medica...
BioCentury | Sep 28, 2018
Clinical News

Cell Medica doses first neuroblastoma patient with NK cell therapy

...maximum tolerated dose (MTD) as its primary endpoint and antitumor response as its secondary endpoint. Cell Medica Ltd....
...neuroblastoma Endpoint: Maximum tolerated dose (MTD); antitumor response Status: Phase I started Milestone: NA Jaime De Leon CMD-501 Cell Medica Ltd. Ganglioside...
BioCentury | Aug 1, 2018
Company News

Management tracks: Hologic, Tricidia

...CMO. He was chief clinical development officer at Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Cancer immunotherapy company Cell Medica Ltd....
Items per page:
1 - 10 of 45